A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

PURPOSE: Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/ MEK signaling. We evaluated the safety and efficacy of the VEGF receptor inhibitor pazopanib and MEK inhibitor trametinib in advanced solid tumors and DTC. PATIENTS AND METHODS: Patients...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Kurzrock, Razelle, Ball, Douglas W., Zahurak, Marianna L., Nelkin, Barry D., Subbiah, Vivek, Ahmed, Shabina, O’Connor, Ashley, Karunsena, Enusha, Parkinson, Rose M., Bishop, Justin A., Ha, Yoonji, Sharma, Rajni, Gocke, Christopher D., Zinner, Ralph, Rudek, Michelle A., Sherman, Steven I., Azad, Nilofer S.
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038784/
https://ncbi.nlm.nih.gov/pubmed/31186313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1881
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料